Evidence map›Paper›PMID 37113743›Full record

ReviewOxidative medicine and cellular longevity2023

Role of Gut Microbiota and Oxidative Stress in the Progression of Transplant-Related Complications following Hematopoietic Stem Cell Transplantation.

Mingxuan Chi, Tao Jiang, Xing He, Haoyu Peng, Yunlong Li, Jiong Zhang, Li Wang, Qing Nian, Kuai Ma, Chi Liu

Open access · hybridAbstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Antioxidants (Basel, Switzerland) · 2025
    Article
  6. Oxidative Stress Early After Hematopoietic Stem Cell Transplant.Transplantation and cellular therapy · 2025
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Mingxuan Chi *Department of Nephrology, Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Tao Jiang *Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.
Xing He *School of Clinical Medicine, Chengdu Medical College, China.
Haoyu PengSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yunlong LiDepartment of Urology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0002-5560-4376
Jiong ZhangDepartment of Nephrology, Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Li WangDepartment of Nephrology, Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.
Qing NianChinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.ORCID https://orcid.org/0000-0001-7986-866X
Kuai MaDepartment of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-8165-1328
Chi LiuDepartment of Nephrology, Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0002-3887-6046
University of Electronic Science and Technology of China · CNChengdu Medical College · CNThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation, has curative potential for various hematologic malignancies but is associated with risks such as graft-versus-host disease (GvHD), severe bloodstream infection, viral pneumonia, idiopathic pneumonia syndrome (IPS), lung fibrosis, and sinusoidal obstruction syndrome (SOS), which severely deteriorate clinical outcomes and limit the wide application of HSCT. Recent research has provided important insights into the effects of gut microbiota and oxidative stress (OS) on HSCT complications. Therefore, based on recent studies, we describe intestinal dysbiosis and OS in patients with HSCT and review recent molecular findings underlying the causal relationships of gut microbiota, OS, and transplant-related complications, focusing particularly on the involvement of gut microbiota-mediated OS in postengraftment complications. Also, we discuss the use of antioxidative and anti-inflammatory probiotics to manipulate gut microbiota and OS, which have been associated with promising effects in improving HSCT outcomes.

Indexed as

Gastrointestinal MicrobiomeHematopoietic Stem Cell TransplantationPneumonia, ViralBone Marrow TransplantationHumansOxidative Stress

Identifiers

PMID37113743
PMCPMC10129428
OpenAlexW4366331251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.